Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to find out whether the combination of pembrolizumab and olaparib is an effective treatment for people with persistent or recurrent endometrial cancer or endometrial carcinosarcoma. The researchers will also look at the safety of the drug combination and whether it causes few or mild side effects in participants.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05156268
Study type Interventional
Source Memorial Sloan Kettering Cancer Center
Contact
Status Active, not recruiting
Phase Phase 2
Start date January 27, 2022
Completion date January 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04106414 - Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment Phase 2
Recruiting NCT05001282 - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±) Phase 1/Phase 2
Active, not recruiting NCT03651206 - Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib Phase 2/Phase 3
Completed NCT03015129 - A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Phase 2